ResMed Shares Dip 0.36 as $380M Trading Volume Surges 61.7% Amid CEO Sales and Analyst Upgrades Highlighting Top 500 Rank

ResMed Inc. (RMD) closed August 12 with a 0.36% decline to $283.29, despite a 61.7% surge in trading volume to $380 million. The stock’s recent performance coincided with insider activity as CEO Michael J. Farrell sold 8,009 shares worth $2.24 million, reducing his ownership by 1.73%. This follows the company’s Q4 fiscal 2025 earnings report, which showed a 10.2% year-over-year revenue increase to $1.35 billion and an EPS of $2.55, exceeding analyst estimates by $0.08.

Analysts remain cautiously optimistic, with UBS Group raising its price target to $325 and William Blair assigning a “strong-buy” rating. The firm also announced a quarterly dividend hike to $0.60 per share, a 13% annualized yield. Institutional ownership remains strong, with 54.98% of shares held by institutions, though short interest has declined by 7.4% month-over-month, signaling improving sentiment.

The strategy of buying the top 500 stocks by daily trading volume and holding for one day yielded a $2,300 profit from 2022 to the present, with a maximum drawdown of -15.7% recorded in early 2023. This highlights the strategy’s moderate risk-reward profile during the period.